NCCN 8th Annual Congress: Hematologic Malignancies™

New York, NY US
September 20, 2013 to September 21, 2013

Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This Congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.

Andrew D. Zelenetz, MD, PhD
Memorial Sloan-Kettering Cancer Center


View agenda

View complete fee details

Target Audience

This congress is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Additional information

This activity is supported by an educational donation provided by Amgen.  This activity is supported by educational grants from Bristol-Myers Squibb; Celgene Corporation; Genentech USA, Inc.; Janssen Biotech, Inc. administered by Janssen Services, LLC., and Pharmacyclics, Inc.; Jazz Pharmaceuticals, Inc.; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Pfizer; Seattle Genetics, Inc.; and Sigma-Tau Pharmaceuticals, Inc.

(As of September 9, 2013)

Course summary
Available credit: 
  • 9.50 Participation
  • 8.07 Nurse
  • 9.50 Pharmacist
  • 9.50 Physician
Course opens: 
Course expires: 
Event starts: 
09/20/2013 - 6:00pm EDT
Event ends: 
09/21/2013 - 5:00pm EDT
New York Marriott Marquis
1535 Broadway
New York, NY 10036
United States

This congress is approved for AMA PRA Category 1 Credit(s)™ for physicians and is also accredited for nurses and pharmacists (ACPE). View complete accreditation details

Available Credit

  • 9.50 Participation
  • 8.07 Nurse
  • 9.50 Pharmacist
  • 9.50 Physician


Please login or register to take this course.